Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
- 1Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, China
- 2Key Laboratory of Cancer Prevention and Therapy of Tianjin, Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- 3Key Laboratory of Cancer Prevention and Therapy, Department of Breast Cancer Pathology and Research Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- 4Department of Respiratory Medicine, Central Hospital of Zibo, Zibo, China
- 5Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China
- 6Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China
- 7Department of Epidemiology and Biostatistics, First Affiliated Hospital, Army Medical University, Chongqing, China
by Chen, H., Chong, W., Wu, Q., Yao, Y., Mao, M., and Wang, X. (2019). Front. Immunol. 10:1113. doi: 10.3389/fimmu.2019.01113
In the published article, there was an error in affiliation “1.” Instead of “Shandong Academy of Clinical Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China,” it should be “Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, China.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: LRP1B, melanoma, NSCLC, tumor mutation burden, immunotherapy, mutation signatures
Citation: Chen H, Chong W, Wu Q, Yao Y, Mao M and Wang X (2019) Corrigendum: Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. Front. Immunol. 10:1523. doi: 10.3389/fimmu.2019.01523
Received: 17 June 2019; Accepted: 18 June 2019;
Published: 02 July 2019.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2019 Chen, Chong, Wu, Yao, Mao and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Min Mao, mmarine510704@hotmail.com; Xin Wang, wangxinmarine@126.com
†These authors have contributed equally to this work